Anavex Life Sciences Received Notice of Noncompliance
Anavex Life Sciences (AVXL) received a notice of noncompliance from Nasdaq on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company's stock continues to trade on the Nasdaq Global Select Market, and it has until July 20, 2026, to submit a compliance plan. If the plan is accepted, Anavex may have until November 16, 2026, to regain compliance.
Nasdaq warns Anavex (Nasdaq: AVXL) over delayed quarterly filing
Anavex Life Sciences Corp. (AVXL) has received a delinquency notification from Nasdaq for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company now has until July 20, 2026, to submit a plan to regain compliance, and potentially until November 16, 2026, to cure the delinquency, otherwise it faces a delisting process. Anavex stresses that it is actively working to complete the filing and submit the required compliance plan.
Nasdaq flags Anavex for missing 10-Q, gives July 20 fix date
Anavex Life Sciences (Nasdaq: AVXL) received a Nasdaq delinquency notification on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan, and stated the notice does not immediately affect its Nasdaq listing. Anavex is actively working to complete and file the delayed Form 10-Q and establish a plan to regain compliance.
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. announced it received an expected delinquency notification from Nasdaq because it failed to timely file its Form 10-Q for the quarterly period ended March 31, 2026. The company has until July 20, 2026, to submit a plan to regain compliance. This notification does not have an immediate effect on the trading of the company's common stock on Nasdaq.
Anavex Life Sciences Announces COO Departure Amid Restructuring
Anavex Life Sciences announced the departure of its Chief Operating Officer, Felix Lauscher, on May 11, 2026, as part of a restructuring following the appointment of Dr. Terrie Kellmeyer as interim CEO. Lauscher, who served only since March 1, 2026, received a prorated salary and some vested stock options, with the company incurring modest financial obligations. This leadership change signals a consolidation of executive roles and potential near-term operational uncertainty for the biopharmaceutical company.
Anavex Life Sciences Announces COO Departure Amid Restructuring
Anavex Life Sciences announced the departure of COO Felix Lauscher on May 11, 2026, as part of a leadership reorganization following the appointment of an interim CEO. Lauscher's short tenure resulted in limited financial impact to the company, indicating a swift management restructuring. Despite weak financial performance and a bearish technical setup, the company highlights a strong cash runway and ongoing regulatory engagement, though near-term uncertainty remains.
Anavex (AVXL) COO exits amid reorganization; option grant largely forfeited
Anavex Life Sciences Corp. announced the departure of its Chief Operating Officer, Felix Lauscher, effective May 11, 2026, as part of a reorganization following the appointment of an Interim CEO. Lauscher forfeited the majority of his 50,000 stock options, retaining only 4,167 vested options. He received a prorated portion of his annual salary and an offer for additional compensation in exchange for a general release.
Anavex (AVXL) interim CEO discloses detailed stock option grants
Anavex Life Sciences' interim CEO, Terrie Kellmeyer, has filed an initial Form 3 detailing her stock option holdings. The filing reveals three grants of common stock options with varying exercise prices, expiration dates, and vesting schedules, including both time-based and performance-based vesting conditions. These options are held directly and primarily consist of long-dated awards extending into the 2030s, establishing her beneficial ownership position.
Anavex Life Sciences (NASDAQ: AVXL) delays 10-Q after CEO termination
Anavex Life Sciences (NASDAQ: AVXL) has announced a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This delay is attributed to an ongoing independent Special Committee review following the termination of its previous CEO on April 30, 2026, and the subsequent appointment of an Interim CEO. The company states that the new Interim CEO requires sufficient time to review and certify the report before it can be filed.
Anavex Life Sciences Names Interim CEO Amid Leadership Shift
Anavex Life Sciences announced a leadership change, terminating CEO Christopher Missling for cause and appointing Terrie Kellmeyer as interim CEO. This transition, which also involves an extension to submit its quarterly report, places Kellmeyer in charge of advancing the company's blarcamesine-led pipeline and regulatory interactions. Despite weak financial performance and regulatory uncertainty noted by analysts, the company aims to reassure stakeholders of its strategic focus and financial stability.
Anavex Life Sciences Names Interim CEO Amid Leadership Shift
Anavex Life Sciences has appointed Terrie Kellmeyer as interim CEO following the termination of Christopher Missling. This leadership change occurs as the company plans to file for an extension for its quarterly report and aims to advance its blarcamesine-led pipeline. Analysts currently rate AVXL as a "Buy" with a $20.00 price target, though AI analysis suggests a "Neutral" outlook due to financial performance and regulatory uncertainties.
Number of shareholders of Anavex Life Sciences Corp. – FWB:12X1
This article provides details on the number of shareholders for Anavex Life Sciences Corp., traded on the Frankfurt Stock Exchange under the ticker FWB:12X1. It specifies that the market is currently closed with no trades. The content offers an overview of the company, financial data, news, and community forecasts related to its stock.
Anavex Life Sciences Appoints Terrie Kellmeyer as Interim CEO Following Christopher Missling’s Departure
Anavex Life Sciences Corp. (Nasdaq: AVXL) has appointed Dr. Terrie Kellmeyer as Interim CEO, replacing Dr. Christopher Missling who departed following a resignation request. This leadership change comes as the company focuses on advancing its lead candidate, oral blarcamesine, for early Alzheimer’s disease, supported by a strong cash balance. The company will also delay its Q1 2026 financial report and plans to provide further updates via a conference call.
CEO ousted as Anavex (NASDAQ: AVXL) board installs interim chief and eyes 10-Q delay
Anavex Life Sciences Corp. announced a significant leadership change, with its board terminating CEO Christopher Missling for Cause and appointing Terrie Kellmeyer, PhD, as Interim CEO. The company also expects to delay its Form 10-Q filing for the quarter ended March 31, 2026. This move, including the CEO's termination and the financial reporting delay, raises governance concerns for the clinical-stage biopharmaceutical company.
Director Axel Paeger files initial Form 3 for Anavex (AVXL)
Anavex Life Sciences Corp. director Axel Paeger has filed an initial Form 3, an SEC document indicating beneficial ownership for company insiders. The filing reports no transactions, exercises, gifts, restructurings, or derivative holdings, serving as a baseline disclosure of Paeger's insider status. This document establishes his reporting obligations as a director but shows no immediate buying or selling activity for AVXL shares.
What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks
Anavex Life Sciences (AVXL) is highlighted as one of the best-shorted penny stocks, with over 500% upside potential. Recent clinical trial data for blarcamesine, particularly in patients with specific genetic markers (SIGMAR1 and COL24A1 wild-type gene), showed strong correlations between decreased atrophy and improved cognitive performance, supporting the company's precision medicine approach. Anavex is developing therapeutics for various diseases including Alzheimer's, cancer, and Rett syndrome, with blarcamesine being its primary drug.
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's
Anavex Life Sciences has requested the European Medicines Agency (EMA) to re-examine its negative opinion regarding the marketing authorization application for blarcamesine. The drug was intended to treat early Alzheimer's disease. The company believes the EMA's decision was based on incomplete information and is hoping to present a stronger case for the drug's approval.
Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health
This article lists the top five trending stocks on Stocktwits, including Webull, SharpLink, Anavex Life Sciences, BigBear.ai, and Oscar Health. It suggests these companies are generating significant discussion among investors on the platform.
Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health
This article lists the top 5 trending stocks on Stocktwits today, including Webull, SharpLink Gaming Ltd., Anavex Life Sciences Corp., BigBear.ai Holdings, Inc., and Oscar Health, Inc. The trends cover various sectors from fintech to healthcare and reflect the current interest among retail investors.
Anavex Life Sciences (NASDAQ:AVXL) Share Price Passes Below 200-Day Moving Average - Time to Sell?
Anavex Life Sciences (NASDAQ:AVXL) saw its stock price drop below its 200-day moving average to $3.50, a level that analysts consider a potential bearish signal. Despite this, institutional investors like State Street and Goldman Sachs have increased their holdings, and the company has a consensus "Hold" rating from analysts with an average price target significantly higher than its current share price. The biotechnology firm recently reported better-than-expected Q4 earnings, surpassing consensus estimates.
Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference
Anavex Life Sciences outlined its strategy for advancing blarcamesine, an oral drug candidate, for neurodegenerative and neurodevelopmental disorders at a Needham conference. The company is focusing on new pivotal trials for early Alzheimer's disease, anticipating an 18-month study with CDR-Sum of Boxes as the primary endpoint. Anavex emphasized blarcamesine's mechanism via autophagy and the sigma-1 receptor, its favorable safety profile (no ARIA), and strong financial position with $130 million in cash.
Anavex Life Sciences Advances Blarcamesine Research, Highlighting Shared Autophagy Mechanisms in Autism and Alzheimer’s Disease
Anavex Life Sciences announced new research findings supporting the potential of its drug blarcamesine for treating autism spectrum disorder (ASD) and Alzheimer's disease (AD). The research highlights shared biological pathways, specifically impaired autophagy and synaptic dysfunction, between the two conditions, with epidemiological data showing a significantly higher incidence of Alzheimer's in autistic adults. Blarcamesine targets the restoration of autophagy via SIGMAR1 activation, having shown promise in preclinical models and clinical trials for AD, Rett syndrome, and Parkinson’s disease dementia.
Autistic adults had up to 8x dementia rates in research Anavex cites
Anavex Life Sciences announced new scientific findings linking autism spectrum disorder (ASD) and Alzheimer’s disease (AD) through shared biological mechanisms like autophagy dysfunction and synaptic pruning deficits. The company cites epidemiological research indicating autistic adults may have up to 8 times higher dementia rates. These findings support Anavex's intent to advance blarcamesine, a SIGMAR1 activator, into pivotal clinical studies, building on its demonstrated effects in previous trials for Alzheimer's, Rett syndrome, and Parkinson's disease dementia.
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Anavex Life Sciences announced new findings highlighting the shared biology between autism spectrum disorder (ASD) and Alzheimer’s disease (AD), focusing on impairments in autophagy and synaptic dysfunction. These findings support the scientific rationale for advancing their orally administered drug, blarcamesine, which targets and restores autophagy through SIGMAR1 activation, into pivotal clinical studies. The company believes this approach can address common CNS disease mechanisms across neurodevelopmental and neurodegenerative conditions.
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Anavex Life Sciences Corp. (AVXL) after the company withdrew its application for marketing authorization of blarcamesine in the EU, causing a significant drop in its stock price. The firm is encouraging shareholders to contact them for more information regarding the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Anavex Life Sciences Corp. (AVXL) following a significant stock price drop. The decline occurred after Anavex withdrew its application for marketing authorization of blarcamesine in the EU, a drug for early Alzheimer's disease, due to negative feedback from the European Medicines Agency. Shareholders who purchased Anavex securities are encouraged to contact the firm for more information.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This decline occurred after Anavex withdrew its application for marketing authorization of blarcamesine in the EU, a treatment for early Alzheimer's disease, due to negative feedback from the European Medicines Agency. The firm encourages investors who purchased Anavex securities to participate in the investigation regarding potential claims.
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. announced it will present at the 25th Annual Needham Virtual Healthcare Conference, scheduled from April 13-16, 2026. President and CEO Christopher U. Missling, PhD, and his management team will present on Tuesday, April 14th, 2026, at 1:30 PM ET. A live audio webcast and archived edition will be available on the company's website.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This decline occurred after Anavex withdrew its application for marketing authorization of blarcamesine in the EU, a decision that followed negative feedback from the European Medicines Agency. The firm is encouraging investors who purchased Anavex securities to participate in the investigation, noting that it represents investors on a contingency fee basis.
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. (AVXL) after the company withdrew its application for marketing authorization of blarcamesine in the EU, causing a significant stock price drop. The firm encourages Anavex shareholders to contact them to assist with the investigation. The investigation stems from Anavex's announcement on March 25, 2026, that the European Medicines Agency (EMA) was not in a position to issue a positive opinion for its Alzheimer's drug application.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This comes after Anavex withdrew its application for blarcamesine's marketing authorization in the EU, a drug for early Alzheimer's disease, due to negative feedback from the European Medicines Agency. The firm is encouraging investors who purchased Anavex securities to contact them for more information regarding potential claims.
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. (AVXL) securities following a significant stock price drop. The drop occurred after Anavex withdrew its application for marketing authorization of blarcamesine in the EU, a decision made after feedback from the European Medicines Agency indicated a positive opinion was unlikely. Anavex investors are encouraged to contact the firm for more information and to assist with the investigation.
Anavex Life Sciences (Nasdaq:AVXL) - Stock Analysis
This report provides a comprehensive stock analysis of Anavex Life Sciences (Nasdaq:AVXL), a biopharmaceutical company focused on neurological disorder therapies. It highlights the company's current stock performance, market capitalization, analyst consensus target price of US$22 (86.4% undervalued), and future growth prospects with earnings forecast to grow 60.57% per year. The analysis also covers its pipeline, financial health, risk factors, and recent news regarding its drug development programs, particularly Blarcamesine, for conditions like Alzheimer's and Parkinson's disease.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This decline occurred after Anavex withdrew its application for marketing authorization of blarcamesine for early Alzheimer's disease in the EU, a decision prompted by feedback from the European Medicines Agency. The firm is encouraging investors who purchased Anavex securities to join their investigation into potential claims.
AVXL Earning Date, Earning Analysis and Earning Prediction
The article provides an earnings analysis and prediction for AVXL (Anavex Life Sciences Corp), detailing past quarterly results and future forecasts. It highlights unchanged revenue and EPS estimates for FY2025 and Q2 2025, and discusses the correlation between earnings revisions and stock price movements. The piece also includes a summary of historical stock reactions around earnings reports and addresses frequently asked questions regarding AVXL's financial performance and outlook.
After withdrawing its EU filing, Anavex keeps Alzheimer’s drug in talks
Anavex Life Sciences provided a regulatory update, withdrawing its EU marketing application for blarcamesine in early Alzheimer's to gather more data and address EMA questions. Concurrently, the company submitted additional data to the FDA to align on a New Drug Application pathway for early Alzheimer's and is engaging EU regulators for blarcamesine in Parkinson’s disease and Rett syndrome. This update emphasizes Anavex's continued commitment to developing innovative oral therapies despite regulatory setbacks.
Anavex Life Sciences Provides Comprehensive Regulatory Update
Anavex Life Sciences has provided a comprehensive regulatory update, continuing dialogue with the European Medicines Agency (EMA) to advance the development program for oral blarcamesine in early Alzheimer’s disease. The company has also submitted additional data to the U.S. FDA to discuss potential pathways for a New Drug Application (NDA) for early Alzheimer's. Furthermore, Anavex is engaging with EU regulators for blarcamesine in Parkinson’s disease and rare diseases like Rett syndrome, showcasing the breadth of its clinical development.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating potential claims on behalf of investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) following the withdrawal of its blarcamesine marketing authorization application in the EU. This decision came after feedback from the European Medicines Agency's Committee for Medicinal Products Human Use (CHMP), which indicated it would not issue a positive opinion. The news led to a significant drop in Anavex's stock price, prompting the law firm's investigation into possible securities fraud.
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences Corp. (NASDAQ: AVXL) shares plummeted after the company withdrew its application for marketing authorization of blarcamesine in the EU for early Alzheimer’s disease. This decision followed negative feedback from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Health (CHMP). The company plans to gather additional data and analyses to address the CHMP's concerns, while also discussing potential pathways for a New Drug Application with the U.S. FDA.
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist
Anavex Life Sciences (AVXL) experienced a catastrophic 31.5% intraday collapse, hitting a new 52-week low despite a resilient broader biotech sector. The plunge is attributed to a technical breakdown, aggressive profit-taking, and a loss of confidence among institutional holders, rather than specific company news. With key support levels breached and oversold conditions, the immediate outlook is precarious, urging investors to watch the $2.85 mark for potential reversal signals.
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback
Anavex Life Sciences has withdrawn its EU marketing authorization application for blarcamesine, intended as an add-on therapy for early Alzheimer’s disease. The decision follows feedback from the CHMP, indicating it would not be in a position to issue a positive opinion at this time. Anavex plans to gather additional data and further analyses while remaining committed to ongoing clinical development.
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine
Anavex Life Sciences Corp. has withdrawn its application for EU marketing authorization of blarcamesine as an add-on therapy for early Alzheimer’s disease. This decision follows feedback from the European Medicines Agency’s CHMP indicating it would not issue a positive opinion at this time. Anavex remains committed to blarcamesine's development and plans to gather additional data to address the CHMP's concerns.
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results
Anavex Life Sciences Corp. (NASDAQ: AVXL) has seen its stock drop by over 30% following unimpressive clinical trial results and an operating loss of $6.78M due to high R&D expenses. Despite financial volatility and investor wariness, the company maintains a strong cash position of $131.75M and a zero-debt-to-equity ratio, indicating financial resilience. The market's reaction hinges on whether Anavex's ongoing research investments will translate into significant breakthroughs and future financial success.
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences' stock fell significantly after the company withdrew its application for marketing authorization of blarcamesine, an Alzheimer's drug, in the EU. This decision came after the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) indicated it would not issue a positive opinion. Anavex plans to gather additional data and conduct further analyses to address the CHMP's concerns, while also exploring pathways for a New Drug Application with the U.S. FDA.
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union.
Anavex Life Sciences Corp. (AVXL) has provided updates on the regulatory review process for its drug Blarcamesine, intended for early Alzheimer's disease, within the European Union. This disclosure aims to inform investors about the progress of this potential treatment. The article emphasizes that its content is solely the author's opinion and not financial advice from the platform.
Anavex Life Sciences stock tumbles after EU filing withdrawal
Anavex Life Sciences (NASDAQ:AVXL) shares fell 12% after the company withdrew its marketing authorization application for blarcamesine in the European Union, intended as a treatment for early Alzheimer’s disease. The withdrawal occurred because the European Medicines Agency's Committee for Medicinal Products for Human Use indicated it would not issue a positive opinion at this time. Anavex plans to gather additional data and conduct further analyses to address the issues raised by the committee.
EU review halts Anavex’s Alzheimer’s drug bid, more data next
Anavex Life Sciences (Nasdaq: AVXL) withdrew its EU marketing authorization application for blarcamesine for early Alzheimer's disease after the EMA's CHMP indicated it would not issue a positive opinion at this time. The company plans to gather additional data, conduct further analyses, and continue clinical development to address the CHMP's feedback. This news led to a significant negative market reaction, with AVXL shares declining by 32.46%.
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences announced the withdrawal of its marketing authorization application for blarcamesine in the EU for early Alzheimer's disease, following feedback from the European Medicines Agency's (EMA) CHMP indicating a positive opinion was unlikely at this time. The company stated it will consider the feedback to gather additional data and analyses to address the points raised, affirming its commitment to developing innovative oral therapies for Alzheimer's patients. Anavex highlighted its intent to engage further with regulatory authorities despite the current setback, which came after initial encouragement from the EMA's SME office.
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Anavex Life Sciences presented new data from its AD-004 Phase IIb/III trial at the AD/PD 2026 Conference, highlighting a consistent correlation between oral blarcamesine treatment and the preservation of brain volume in early Alzheimer’s disease. The data indicate that blarcamesine's clinical effects are biologically consistent with neuroprotection measured by MRI, particularly benefiting a genetically defined patient population. Long-term clinical data also suggest significant time saved in cognitive decline compared to a control group, reinforcing blarcamesine's potential as a disease-modifying treatment.
Study ties oral Alzheimer’s drug to slower brain shrinkage
Anavex Life Sciences presented new data from its AD-004 Phase IIb/III trial for blarcamesine in early Alzheimer's disease, showing a consistent correlation between the treatment and preservation of brain volume. The findings indicate patients treated with oral blarcamesine experienced 77.4 weeks of time saved versus a control group and highlight a strong MRI-clinical endpoint coherence, particularly in a genetically defined subgroup. While results are investigational, the company emphasizes the drug's oral convenience and potential for precision medicine in Alzheimer's treatment.
